Alnylam Pharmaceuticals, Inc.

Epix Delaware, Inc.

Predix Pharmaceuticals Holdings, Inc.

Trovis Pharmaceuticals, LLC

Venkitasamy Kesavan

Muthiah Manoharan

Kallanthottathil G Rajeev

Oren Becker

Srinivasa Rao Cheruku

Yael Marantz

Dale S Dhanoa

Silvia Noiman

Dongli Chen

Boaz Inbal

Alexander Heifetz

Shay Bar-Haim

Anurag Sharadendu

Sharon Shacham

Rosa Melendez

A Sekar Reddy

Sharon Shachem

Sekar A Reddy

Rosa E Mele'ndez

Sekar Reddy Alla

Rosa E Melendez

The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.

Modified iRNA agents

This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression.

Ligand-conjugated monomers

The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.

The present invention provides single-stranded and double-stranded oligonucleotides comprising at least one aralkyl ligand that improvise the pharmacokinetic properties of the oligonucleotide. The aralkyl ligands of the present invention include naproxen, ibuprofen, and derivatives thereof. The present invention also provides method for modulating gene expression using the modified oligonucleotide compounds and compositions comprising those modified oligonucleotides.

Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety

Chemically modified oligonucleotides

The present invention provides single-stranded and double-stranded oligonucleotides comprising at least one aralkyl ligand that improves the pharmacokinetic properties of the oligonucleotides. The aralkyl ligands of the present invention include naproxen, ibuprofen and derivatives thereof. The present invention also provides methods for modulating gene expression using the modified oligonucleotide compounds and compositions comprising those modified oligonucleotides.

The invention relates to 5-HT receptor modulators, particularly 5-HTantagonists. Novel piperidinylamino-thieno[2,3-d]pyrimidine compounds represented by Formula I, II and III, and uses thereof for treating conditions including pulmonary arterial hypertension, congestive heart failure, and hypertension.

Piperidinylamino-thieno[2,3-D] pyrimidine compounds

The invention relates to 5-HT receptor antagonists. Novel piperidinylamino-thieno[2,3-d] pyrimidine compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as anxiety, depression, schizophrenia, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

Piperidinylamino-thieno[2,3-d] pyrimidine compounds

Growing community of inventors

Woburn, MA, United States of America

Venkitasamy Kesavan